Hookipa Biotech

Hookipa Biotech Initiates First-in-Human Study of Cytomegalovirus Vaccine

Vienna, Austria, July 20, 2016 -- Hookipa Biotech AG, a company pioneering a new class of immunotherapies and vaccines, based on its proprietary viral vector platform Vaxwave, today announces the start of a first-in-human study to evaluate the safety and immunogenicity of its vaccine candidate, HB-101, against human cytomegalovirus (HCMV). Part of the herpes family...

J??rn Aldag Appointed CEO of Hookipa Biotech

Immunotherapy and vaccines company announces the appointment of Mr Jˆrn Aldag as CEO
Helmut-Qualtinger-Gasse 2, 1030 Vienna, Austria

+43 1 890 63 60